Conclusions and Future Directions

↳ This is a section part of Moment: Statins: Practical Considerations – A Review

Add this Moment to your Passport

Learn from this moment and keep it forever.
FREE
Add To Passport

Preview

Summary

Conclusions and Future Directions

Statin use is expected to increase with the adoption of the new 2013 ACC/AHA Cholesterol guidelines, bringing new challenges for prescribers, with a focus on fixed-dose statins independent of baseline or achieved LDL-C levels. The intensity of statin dose is matched to a person’s baseline ASCVD risk. This is in contrast to the adapted EAS/ESC guidelines in Europe, which recommend tailoring therapy to target specific LDL-C levels. Statin intolerance is not uncommon and can be challenging to manage; however, several therapeutic strategies have been successful in achieving statin tolerance. Although statin use is associated with liver enzyme elevations and increased risk of incident diabetes, there continues to be a net benefit to statins. Individualised risk assessment and discussion of benefits and risks of statin therapy will likely lead to improved adherence and outcomes.

Loading Simple Education